We are persuaded that concluding that the value of anti-RBD IgG is a (relatively) poor marker of neutralizing bioactivity seems unwarranted at this point in time, provided that this has not been asserted using live virus neutralization assays. It shall also be clearly acknowledged that the current performance of the many commercial immunoassays that measure neutralizing anti-SARS-CoV-2 antibodies vary significantly when compared with the gold standard technique, as recently shown in a study that compared five anti-SARS-CoV-2 IgG chemiluminescent techniques with a plaque reduction neutralization test (PRNT) (i.e., correlations between 0.799 and 0.872). Finally, the clinical significance of the many currently available anti-SARS-CoV-2 IgG immunoassays needs to be tested and validated in patients infected by highly mutated variants, such as the recently emerged Omicron (B.1.1.529) strain.
Not all SARS-CoV-2 IgG and neutralizing antibody assays are created equal
Lippi, Giuseppe
;
2022-01-01
Abstract
We are persuaded that concluding that the value of anti-RBD IgG is a (relatively) poor marker of neutralizing bioactivity seems unwarranted at this point in time, provided that this has not been asserted using live virus neutralization assays. It shall also be clearly acknowledged that the current performance of the many commercial immunoassays that measure neutralizing anti-SARS-CoV-2 antibodies vary significantly when compared with the gold standard technique, as recently shown in a study that compared five anti-SARS-CoV-2 IgG chemiluminescent techniques with a plaque reduction neutralization test (PRNT) (i.e., correlations between 0.799 and 0.872). Finally, the clinical significance of the many currently available anti-SARS-CoV-2 IgG immunoassays needs to be tested and validated in patients infected by highly mutated variants, such as the recently emerged Omicron (B.1.1.529) strain.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
